Epidermal growth factor receptor expression in anal canal carcinoma.

Most anal canal carcinomas (ACCs) are squamous cell carcinomas (SCCs). SCCs in other tumor sites strongly express epidermal growth factor receptors (EGFRs), the inhibition of which might result in favorable changes in tumor growth. A review of the published scientific literature reveals no information regarding the expression of EGFR in ACCs. Therefore, we obtained archived pathology samples from ACC biopsies and examined the frequency and level of expression of EGFR and other cell surface and cell cycle markers. The 21 samples studied universally and strongly expressed EGFR and were negative for HER-2. Clinical studies of EGFR inhibitors in advanced ACC are warranted.

[1]  W. Evans.  Gefitinib does not improve survival when combined with paclitaxel and carboplatin chemotherapy in people with advanced non-small-cell lung cancer. , 2004, Cancer treatment reviews.

[2]  J. Rigas,et al.  Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  P. LoRusso,et al.  Targeting the epidermal growth factor receptor , 2004, British Journal of Cancer.

[4]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[5]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[6]  Roy S Herbst,et al.  Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Clark,et al.  Cancer of the anal canal. , 2004, The Lancet. Oncology.

[8]  G. Giaccone,et al.  Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  M. Hidalgo,et al.  Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Rezola,et al.  p53 and Cyclin D1 as Prognostic Factors in Squamous Cell Carcinoma of the Larynx , 2003, The Laryngoscope.

[12]  J. Molnár,et al.  Ki-67, cyclin D1, p53 and bcl-2 expression in advanced head and neck cancer. , 2003, In vivo.

[13]  S. Ell,et al.  Overexpression of Bcl‐2 in squamous cell carcinoma of the larynx: A marker of radioresistance , 2002, International journal of cancer.

[14]  A. Vecchione,et al.  Prognostic impact of CD31 antigen expression in anal canal carcinoma. , 2001, Hepato-gastroenterology.

[15]  H. Skomedal,et al.  Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas , 2001, Histopathology.

[16]  S. Shintani,et al.  Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma , 2001, International journal of cancer.

[17]  E. Srivatsan,et al.  Antisense Cyclin D1 Enhances Sensitivity of Head and Neck Cancer Cells to Cisplatin , 2001, The Laryngoscope.

[18]  A. Vecchione,et al.  Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. , 2000, Journal of experimental & clinical cancer research : CR.